Anticoagulation and Antiplatelet Therapy Monitoring

Introduction to Anticoagulation and Antiplatelet Therapy

The American Academy of Family Physicians recommends a standard therapeutic range of INR 2.0-3.0 for most indications when using warfarin, an anticoagulant that inhibits vitamin K-dependent clotting factors 1
For specific conditions like mechanical heart valves, the American Heart Association recommends a higher target INR range of 2.5-3.5 when using warfarin 2

The American Academy of Family Physicians recommends an INR target of 2.0-2.5 for triple therapy, which includes warfarin, clopidogrel, and aspirin, with low-dose aspirin (75-81 mg) 1
For dual therapy, which includes warfarin and clopidogrel, the American Academy of Family Physicians recommends an INR target of 2.0-3.0, with close monitoring due to increased bleeding risk 1
Close monitoring is essential for patients on dual therapy (warfarin and clopidogrel) due to increased bleeding risk, as stated by the American Heart Association 3

The combination of warfarin and antiplatelet therapy significantly increases bleeding risk, and patients on this combination require careful monitoring, according to the American Academy of Family Physicians 1
The use of point-of-care INR devices is not recommended in patients with antiphospholipid antibodies, as they can give inaccurate results, as noted by a medical guideline society 4

Clopidogrel's effectiveness is not reflected in PT/INR values, and attempting to adjust clopidogrel dosing based on PT/INR results would be inappropriate and potentially harmful, as it works through a completely different mechanism than warfarin, inhibiting platelet aggregation by irreversibly blocking the P2Y12 receptor on platelets 1